Among the mentioned FLT3 inhibitors, only two molecules, including midostaurin (Rydapt®) and gilteritinib (Xospata®), have been approved by the FDA for the treatment of FLT3-mutated AML in 2017 and 2018, respectively. The gene discussed is FLT3; the disease is acute myeloid leukemia.